ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Teetering Akorn hit with another FDA warning letter fiercepharma
June 28, 2019For Akorn, when it rains, it monsoons. The sterile and generics maker, whose $4.3 billion buyout by Fresenius was swept away because of manufacturing failures, has received its second warning letter this year, even as it is in the process of renegotiating
Pharma Sources Insight January 2025
